Financial Performance - The company's revenue for Q1 2025 reached ¥38,486,755.18, representing a 125.44% increase compared to ¥17,072,014.53 in the same period last year[5] - Net profit attributable to shareholders was ¥6,011,717.89, a significant turnaround from a loss of ¥3,614,700.21, marking a 266.31% increase[5] - Basic earnings per share rose to ¥0.0971, compared to a loss of ¥0.0584 per share in the same period last year, an increase of 266.27%[5] - Operating profit for the current period was ¥7,697,548.76, compared to a loss of ¥3,855,549.76 in the previous period, marking a turnaround in profitability[17] - The total profit for the current period is 7,697,548.97, compared to a loss of 3,846,088.51 in the previous period[18] Cash Flow - The net cash flow from operating activities improved to ¥5,178,293.83, compared to a negative cash flow of ¥13,297,768.57 in the previous year, reflecting a 138.94% increase[5] - Cash flow from operating activities generated a net amount of 5,178,293.83, a significant improvement from a loss of 13,297,768.57 in the previous period[21] - Cash flow from investing activities resulted in a net outflow of 241,459,890.55, compared to a net inflow of 111,332,488.26 in the previous period[21] - The ending cash and cash equivalents balance is 331,525,326.47, up from 282,097,719.99 in the previous period[21] - Total cash inflow from operating activities is 51,642,714.27, compared to 39,118,812.34 in the previous period[21] Research and Development - The company reported a 37.56% increase in R&D expenses, totaling ¥10,167,422.37, driven by higher labor costs and material expenses for research projects[8] - Research and development expenses increased to ¥10,167,422.37 from ¥7,391,415.54, reflecting a rise of approximately 37.8%[17] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥1,546,120,649.26, a slight increase of 0.15% from ¥1,543,851,598.21 at the end of the previous year[5] - Total liabilities decreased to ¥36,479,833.11 from ¥40,627,359.79, a reduction of about 10.6%[15] - The company's total equity rose to ¥1,509,640,816.15 from ¥1,503,224,238.42, an increase of approximately 0.4%[16] - The company’s total liabilities increased by 65.31% in accounts payable, reaching ¥15,863,195.30, attributed to increased procurement of raw materials for automation projects[8] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,089[9] - The largest shareholder, Cai Qingsheng, holds 39.68% of the shares, totaling 24,563,925 shares[9] - The second-largest shareholder, Xiamen Rongyu Jiahong Investment Partnership, holds 9.71% of the shares, totaling 6,007,500 shares[9] - A total of 31,128,750 shares are subject to lock-up restrictions, with 1,078,707 shares released during the reporting period[11] - The top ten shareholders do not participate in margin financing or securities lending activities[10] Other Income and Expenses - Other income surged by 330.37% to ¥3,418,661.11, mainly due to an increase in government subsidies received during the reporting period[8] - The company reported a net credit impairment loss of ¥1,313,169.77, compared to ¥893,124.38 in the previous period, indicating an increase in credit losses[17] - The company paid 22,377,814.38 in cash to employees, down from 24,966,209.91 in the previous period[21] Investments - The company acquired 70% equity in Hangzhou Xunqi Medical Technology Co., Ltd. from Liu Yanhua, with the transfer amount being 0 due to unpaid capital contributions[12] - The company invested HKD 12 million to subscribe for 267,608 new shares of Yiling Technology Co., Ltd., representing 10% of the total share capital post-issuance[12] - A wholly-owned subsidiary was established in Germany with an investment of EUR 25,000, named Doppler Electronic Technologies (Europe) GmbH[12] Audit Information - The company has not undergone an audit for the first quarter report[22]
多浦乐(301528) - 2025 Q1 - 季度财报